Research Paper Volume 13, Issue 17 pp 21268—21282

Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism

Regulator of MitoBiogenesis proteins and OXPHOS Subunits were modulated by celecoxib in GBM LN229 and LN18 cells. (A, B) LN229 and LN18 cells (2×105) were seeded into 6-well plates, (three independent wells per condition) following TMZ and/or celecoxib treatment for 48 hours prior to assay. Then the lysates harvested were analyzed by Western blotting for various proteins using Beta-Actin as a loading control as indicated. The COX-II was down-regulated by Celecoxib. The OXPHOS Subunits such as complex I, II, V were down-regulated by celecoxib compare the Beta-actin as standard. And the TFAM which was the regulator MitoBiogenesis protein also was down regulated in LN229. The MitoBiogenesis proteins NRF2 was downregulated by celecoxib, combination therapy was more significant. The LC3 protein tends to increase when the LN229 and LN18 were treated with celecoxib and combination.

Figure 5. Regulator of MitoBiogenesis proteins and OXPHOS Subunits were modulated by celecoxib in GBM LN229 and LN18 cells. (A, B) LN229 and LN18 cells (2×105) were seeded into 6-well plates, (three independent wells per condition) following TMZ and/or celecoxib treatment for 48 hours prior to assay. Then the lysates harvested were analyzed by Western blotting for various proteins using Beta-Actin as a loading control as indicated. The COX-II was down-regulated by Celecoxib. The OXPHOS Subunits such as complex I, II, V were down-regulated by celecoxib compare the Beta-actin as standard. And the TFAM which was the regulator MitoBiogenesis protein also was down regulated in LN229. The MitoBiogenesis proteins NRF2 was downregulated by celecoxib, combination therapy was more significant. The LC3 protein tends to increase when the LN229 and LN18 were treated with celecoxib and combination.